Trial Profile
An Open-Label, 3-Period, Fixed-Sequence Study to Evaluate the Effect of Famotidine and Omeprazole on MK0518 Pharmacokinetics in HIV-Infected Patients on a Stable MK0518-Containing Regimen
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Raltegravir (Primary) ; Famotidine; Omeprazole
- Indications HIV-1 infections
- Focus Pharmacokinetics
- Sponsors Merck & Co
- 03 Nov 2009 New trial record